ACIP Backs Transition To Bivalent COVID-19 Vaccine, Flexibility On Number Of Annual Doses
Executive Summary
The CDC panel supports transition away from the monovalent vaccine to simplify the schedule and reduce errors, but says more data is needed. Members disagree on whether children will need a primary series and favor the option for older adults and the immunocompromised to be vaccinated twice a year.
You may also be interested in...
For Recombinants To Approach mRNA Speed, US FDA Urged To Select Monovalent COVID Boosters
US FDA and BARDA ask makers of recombinant protein SARS-CoV-2 vaccines how they could match mRNA vaccines in post-strain-selection turnaround time for annual booster doses. The reply: give them a fighting chance by selecting just one strain instead of two.
Harmonizing COVID Vaccine Schedule Good Idea, But US FDA Should Remain Flexible, Advisors Say
Vaccines and Related Biological Products Advisory Committee also said that more data is needed to determine the groups that potentially could receive more than one periodic vaccine booster.
FDA Requirements For Next Round Of COVID Vaccines Unclear
Peter Marks tells the Pink Sheet that FDA isn’t ready to say when Americans might need additional COVID shots or what data would be required of sponsors. It’s just one of the ways the country isn’t as close to achieving a flu vaccine-like strategy for COVID as the Biden administration suggests.